Q3 Revenue Climbs 11% YoY as Margins Expand, Board Declares $0.16 Dividend
NRC sits 91% above its 52-week low of $11.32.
Summary
NRC Health posted Q3 2026 revenue growth of 11% year over year with sequential margin expansion and net income of USD 4.704 million, a step up from the Q2 print that showed a GAAP loss driven by one-time stock comp charges. The board declared a $0.16 quarterly dividend payable Jan 8, 2027 to shareholders of record Dec 29, 2026, backing up the cash-return story alongside the existing $60M buyback. Management also flagged a large customer going live and multi-year renewals signed, which supports recurring revenue durability and lowers execution risk on the growth ramp. The release stops short of a full revenue, margin and cash-flow print or a guidance raise, so the hard numbers and any outlook change are still the missing piece. This lands after the August CFO resignation and the October 8-K naming CEO Trent Green interim principal financial officer, so the finance bench remains thin while results improve.
At the time of this announcement, NRC was trading at $21.58 on NASDAQ in the Technology sector, with a market capitalization of approximately $477.3M. The 52-week trading range was $11.32 to $23.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.